11.35
+7.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Corvus Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Corvus Pharmaceuticals is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CRVS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $15.3m. At that date it held total assets of $71.1m and shareholders' equity of $61.2m.
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. Based on the proposed mechanism of action, we believe soquelitinib has the potential to be utilized to inhibit the production of a number of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis and fibrotic diseases. In preclinical studies, Soquelitinib has affected T cell differentiation leading to enhanced function of T cells involved in tumor cell eradication.
Since the immune cells targeted by our product candidates play a role in many diseases, our strategy is to leverage our research and development capabilities by evaluating our product candidates in clinical trials where there is an understanding of the role of specific T cells in the target indication and where we believe such product candidates have the broadest potential. We believe this strategy has enabled us to move rapidly from preclinical to clinical trials in diverse disease areas, each with large unmet needs.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Mar 2016
- Employees
- 37
- Website
- corvuspharma.com ↗
- Head office
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard MillerChairman of the Board, President, Chief Executive Officer, since 2014$3.1m
- Mr. Leiv LeaChief Financial Officer, since 2019$1.6m
- Mr. Jeffrey ArcaraSenior Vice President, Chief Business Officer
- Dr. William JonesSenior Vice President - Pharmaceutical Development$1.6m
- Mr. David MooreDirector
- Mr. Ian ClarkIndependent Director$70,271
- Dr. Linda GraisIndependent Director$74,271
- Mr. Scott MorrisonIndependent Director$86,271
- Dr. Peter ThompsonIndependent Director$72,271
- Mr. Richard van Den BroekIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 37
- Environment
- 38
- Social
- 50
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Corvus Pharmaceuticals Inc has an experienced management team with a strong track record in the biopharmaceutical industry.
- The company has a robust pipeline of innovative cancer immunotherapy drugs, which positions it well in the growing field of immuno-oncology.
- Corvus Pharmaceuticals Inc has established strategic partnerships with reputable pharmaceutical companies, providing access to additional resources and expertise.
Weaknesses
- The company's reliance on a limited number of drug candidates for revenue generation exposes it to higher risks associated with clinical trial failures.
- Corvus Pharmaceuticals Inc may face challenges in securing sufficient funding for its research and development activities, resulting in potential delays in product development.
- The company operates in a highly competitive industry, facing intense competition from well-established pharmaceutical companies and emerging biotech firms.
Opportunities
- The increasing prevalence of cancer globally presents a significant opportunity for Corvus Pharmaceuticals Inc to address unmet medical needs and capture market share.
- The growing demand for personalized medicine and targeted therapies provides an opportunity for the company to develop and commercialize specialized cancer treatments.
- Corvus Pharmaceuticals Inc can leverage advancements in technology and data analysis to enhance its drug discovery and development processes, improving efficiency and reducing costs.
Threats
- The regulatory environment for drug approval and market access is complex and subject to change, posing a threat to Corvus Pharmaceuticals Inc's ability to commercialize its products.
- Competition in the immuno-oncology space is intensifying, with larger pharmaceutical companies investing heavily in research and development, potentially eroding the company's market share.
- The COVID-19 pandemic and its impact on healthcare systems and global economies create uncertainties that could disrupt clinical trials, supply chains, and market conditions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.